Literature DB >> 8178438

Assembly of the major and the minor capsid protein of human papillomavirus type 33 into virus-like particles and tubular structures in insect cells.

C Volpers1, P Schirmacher, R E Streeck, M Sapp.   

Abstract

Native virions of human papillomaviruses (HPV) can be isolated from genital lesions only in very limited amounts. Recent studies have shown that virus-like particles can be obtained by expression of the capsid proteins using vaccinia virus recombinants or the baculovirus system. We now present the first detailed characterization of virus-like particles of a human papillomavirus associated with malignant genital lesions, HPV-33, produced in high yield using the baculovirus expression system. Assembly of the major capsid protein L1 alone or together with the minor capsid protein L2 has been obtained. Both spherical virus-like particles of 50-60 nm diameter and tubular structures of either 25-30 nm or 50-60 nm diameter and variable length were extracted from nuclei of the infected insect cells. However, predominantly 50- to 60-nm spherical particles were found in the cell culture medium in long-term infections. The particles have icosahedral symmetry and a density of 1.29 g/cm3 in cesium chloride corresponding to empty papillomavirus capsids. Immunoelectron microscopy confirmed the presence of L1 and L2 in the virus-like particles. The L2 protein seemed to be modified and was shown to be tightly associated with L1 using density gradient and sedimentation analysis. Approximately 50% of the L1 molecules are cross-linked by intermolecular disulfide bonds. This is the first example for the production of HPV-like particles containing both the major and the minor capsid protein using the baculovirus expression system.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8178438     DOI: 10.1006/viro.1994.1213

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  42 in total

1.  DNA-induced structural changes in the papillomavirus capsid.

Authors:  C Fligge; F Schäfer; H C Selinka; C Sapp; M Sapp
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 2.  Human papillomavirus therapy for the prevention and treatment of cervical cancer.

Authors:  Samir N Khleif
Journal:  Curr Treat Options Oncol       Date:  2003-04

3.  Further evidence that papillomavirus capsids exist in two distinct conformations.

Authors:  Hans-Christoph Selinka; Tzenan Giroglou; Thorsten Nowak; Neil D Christensen; Martin Sapp
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

4.  Modeling the step of endosomal escape during cell infection by a nonenveloped virus.

Authors:  Thibault Lagache; Olivier Danos; David Holcman
Journal:  Biophys J       Date:  2012-03-06       Impact factor: 4.033

5.  Identification of the alpha6 integrin as a candidate receptor for papillomaviruses.

Authors:  M Evander; I H Frazer; E Payne; Y M Qi; K Hengst; N A McMillan
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

6.  Characterization of late gene transcripts expressed during vegetative replication of human papillomavirus type 31b.

Authors:  M A Ozbun; C Meyers
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

7.  Generation and neutralization of pseudovirions of human papillomavirus type 33.

Authors:  F Unckell; R E Streeck; M Sapp
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

8.  Human papillomavirus infection requires cell surface heparan sulfate.

Authors:  T Giroglou; L Florin; F Schäfer; R E Streeck; M Sapp
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

Review 9.  The evolving field of human papillomavirus receptor research: a review of binding and entry.

Authors:  Adam B Raff; Andrew W Woodham; Laura M Raff; Joseph G Skeate; Lisa Yan; Diane M Da Silva; Mario Schelhaas; W Martin Kast
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

10.  Papillomavirus assembly requires trimerization of the major capsid protein by disulfides between two highly conserved cysteines.

Authors:  M Sapp; C Fligge; I Petzak; J R Harris; R E Streeck
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.